FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P <sub>1</sub> ) modulation
Ji Woong Choi(Scripps Research Institute), Jerold Chun(Sanford Burnham Prebys Medical Discovery Institute), Melissa Lu(Scripps Research Institute), Yun C. Yung(Sanford Burnham Prebys Medical Discovery Institute), Grace Kennedy(Sanford Burnham Prebys Medical Discovery Institute), Deron R. Herr(Scripps Research Institute), Chang‐Wook Lee(Scripps Research Institute), Siew T. Teo(Scripps Research Institute), Shannon E. Gardell(Scripps Research Institute), Richard Rivera(Scripps Research Institute), Kyoko Noguchi(Scripps Research Institute)
Cited by 578
Related Papers
Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain
|Nature Biotechnology|2017|1.1k
Neuronal subtypes and diversity revealed by single-nucleus RNA sequencing of the human brain
|Science|2016|1.1k
LPA Receptors: Subtypes and Biological Actions
|The Annual Review of Pharmacology and Toxicology|2010|851
The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak
|Nature Medicine|2007|820
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
|Clinical Neuropharmacology|2010|794